D. E. Shaw & Co., Inc. Sage Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 720,105 shares of SAGE stock, worth $5.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

720,105

Previous 647,032 11.29%

Holding current value

$5.26 Million

Previous $4.67 Million 16.18%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.78 - $8.57 $349,288 - $626,235	73,073 Added 11.29%	720,105 $3.91 Million
Q3 2024 Nov 14, 2024	BUY	$7.02 - $13.08 $2.27 Million - $4.22 Million	322,761 Added 99.53%	647,032 $4.67 Million
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $1.74 Million - $2.95 Million	164,933 Added 103.51%	324,271 $3.52 Million
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $1.78 Million - $2.57 Million	-95,329 Reduced 37.43%	159,338 $2.99 Million
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $897,151 - $1.17 Million	52,465 Added 25.95%	254,667 $5.52 Million
Q3 2023 Nov 14, 2023	SELL	$16.75 - $48.98 $4.17 Million - $12.2 Million	-249,070 Reduced 55.19%	202,202 $4.16 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $123,454 - $180,822	3,037 Added 0.68%	451,272 $21.2 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $5.26 Million - $6.58 Million	-141,214 Reduced 23.96%	448,235 $18.8 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $3.61 Million - $4.89 Million	-112,035 Reduced 15.97%	589,449 $22.5 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $1.91 Million - $2.56 Million	-59,201 Reduced 7.78%	701,484 $27.5 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $4.56 Million - $6.3 Million	-165,851 Reduced 17.9%	760,685 $24.6 Million
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $2.08 Million - $3.1 Million	-67,733 Reduced 6.81%	926,536 $30.7 Million
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $9.71 Million - $12.3 Million	-262,022 Reduced 20.86%	994,269 $42.3 Million
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $2.45 Million - $3.49 Million	-60,852 Reduced 4.62%	1,256,291 $55.7 Million
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $30.4 Million - $44 Million	-554,732 Reduced 29.64%	1,317,143 $74.8 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $22.8 Million - $31.3 Million	-323,012 Reduced 14.72%	1,871,875 $140 Million
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $15.7 Million - $23.9 Million	-268,179 Reduced 10.89%	2,194,887 $190 Million
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $14 Million - $21.3 Million	340,910 Added 16.06%	2,463,066 $151 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $44.3 Million - $73.7 Million	1,708,926 Added 413.55%	2,122,156 $88.2 Million
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $8.8 Million - $26 Million	336,537 Added 438.81%	413,230 $11.9 Million
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $1.62 Million - $4.17 Million	-26,950 Reduced 26.0%	76,693 $5.54 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $14.3 Million - $19.4 Million	102,097 Added 6603.95%	103,643 $14.5 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $13.4 Million - $16.5 Million	-97,363 Reduced 98.44%	1,546 $218,000
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $13 Million - $16.2 Million	92,366 Added 1411.68%	98,909 $15.5 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $4.79 Million - $6.06 Million	-31,500 Reduced 82.8%	6,543 $1.05 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $2.31 Million - $6.37 Million	38,043	38,043 $6.27 Million

Others Institutions Holding SAGE

# of Institutions

194

Shares Held

45M

Call Options Held

304K

Put Options Held

117K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $434M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account